Indazole derivatives as inhibitors of hormone sensitive lipase
The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.
1. An indazole derivative of the formula II
in which the meanings are:
W is —(C═O);
X is C—R;
Y is —O—;
R is hydrogen, halogen, (C 1 -C 6 )-alkyl, (C 1 -C 3 )-alkyloxy-(C 1 -C 3 )-alkylene, hydroxy, (C 1 -C 6 )-alkylmercapto, amino, (C 1 -C 6 )-alkylamino, di-(C 2 -C 12 )-alkylamino, mono-(C 1 -C 6 )-alkylaminocarbonyl, di-(C 2 -C 8 )-alkylaminocarbonyl, COOR4, cyano, trifluoromethyl, (C 1 -C 6 )-alkylsulfonyl, (C 1 -C 6 )-alkylsulfinyl, aminosulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 )-aryl, CO—NR2R3, O—CO—NR2R3, O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—NR2R3 or unsubstituted or mono- or poly- F-substituted (C 1 -C 6 )-alkyloxy;
R1 is H, (C 1 -C 6 )-alkyl or benzyl;
R2 and R3 together with the nitrogen atom carrying them form piperidine which optionally comprises the atomic member CHR5 in position 4;
R4 is hydrogen, (C 1 -C 6 )-alkyl or benzyl;
R5 is (C 1 -C 6 )-alkyl, halogen, trifluoromethyl, or cyclopropylene;
and the physiologically tolerated salts thereof as well as its tautomeric forms.
2. The indazole derivative of claim 1 , wherein
X in position 4, 5 and 7 is C—R with R=hydrogen.
3. The indazole derivative of claim 1 , wherein
W is —(C═O)—;
X is C—R;
Y is —O—;
R is hydrogen, halogen, (C 1 -C 6 )-alkyl, hydroxy, amino, COOR4, trifluoromethyl, (C 1 -C 6 )-alkylsulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 )-aryl, CO—NR2R3, O—CO—NR2R3 or O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl;
R1 is H, (C 1 -C 6 )-alkyl or benzyl;
R2 and R3 together with the nitrogen atom carrying them form piperidine which optionally comprises the atomic member CHR5 in position 4;
R4 is hydrogen, (C 1 -C 6 )-alkyl or benzyl; and
R5 is (C 1 -C 6 )-alkyl, halogen, trifluoromethyl or cyclopropylene.
4. The indazole derivative of claim 1 , wherein
NR2R3 is piperidine which comprises the atomic member CHR5 in position 4.
5. A pharmaceutical composition comprising one or more of the indazole derivatives of claim 1 and a pharmaceutically acceptable carrier.